about
Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrumsChemoenzymatic synthesis of heparan sulfate and heparinCatastrophic antiphospholipid syndrome: a clinical reviewThe potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trialDiagnosis and management of catastrophic antiphospholipid syndrome.Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study.Fondaparinux as a treatment option for heparin-induced thrombocytopenia.Determinants of PF4/heparin immunogenicityAnti-platelet antibodies in a natural animal model of sulphonamide-associated thrombocytopaenia.Acute adrenal insufficiency associated with heparin-induced thrombocytopenia.Heparin induced thrombocytopenia with thrombosis: a two step process?Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopeniaCurrent concepts review: heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia associated with intra-tumour haemorrhage in cavernous sinus after cardiac myxoma surgery.Optimization of a murine immunization model for study of PF4/heparin antibodies.Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacementHeparin-induced thrombocytopenia successfully treated with fondaparinux.Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.Evaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia.Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.Heparin-induced thrombocytopenia: overview and treatment.A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients.Drug-induced hematologic syndromesThrombocytopenia following percutaneous coronary intervention.Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.A rare and undesirable complication of heparin-induced thrombocytopenia: acute massive pulmonary embolism.Use of bivalirudin for heparin-induced thrombocytopaenia after thrombolysis in massive pulmonary embolism: a case report.Fondaparinux: does it cause HIT? Can it treat HIT?Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition.A painful HIT.Heparin-induced thrombocytopenia: present and future.Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literatureUse of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature.An overview of heparin-induced thrombocytopenia.Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?Acute bioprosthetic mitral valve stenosis in a patient with HITS.Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients.Heparin-induced thrombocytopenia in the presence of a heparin-bonded bypass graft.Incidence of isolated heparin-induced thrombocytopenia and risk of thrombosis by IgG-specific anti-PF4/heparin ELISA.
P2860
Q26799395-F657C150-5330-4888-AF40-66F3DCA0D2A5Q27005958-94BBD1E6-A477-41B6-9FF3-AE8DB9C1E0ABQ27009935-4B8AAACB-870A-4A38-BC1B-25A88C51B87BQ28535471-01C55005-519B-49FE-8B4A-A78CCE9CC342Q30235356-9A13CB52-2A93-4B25-8777-2BD52A618581Q33373310-570BDE8B-FA17-4786-AF63-CF2B1F670A72Q33375448-5F628242-7618-4FDE-B5D1-021DFED2A6F8Q33376629-28AC4636-F4E8-47DC-AE96-970C895A77EDQ33377564-CB525226-C423-467A-B770-B1F47812B8ABQ33380067-A83CBDA1-352E-4116-A21C-F29493772A2EQ33380753-D57E3CD8-C0B0-4971-87C7-9637B0A270A2Q33381447-0E335E2A-0C39-41A0-9A5D-C4C425D9BD20Q33382108-D57FA638-CF63-4EB7-89C3-1B83344E46C9Q33383397-7D454921-C3DF-46B9-9A07-EBE1A19097D5Q33383456-95C985E9-727C-40E6-9E0A-492960EAB3A0Q33384243-F989AAF2-F4F8-4816-84DC-F973C5C89282Q33384452-6848F7CE-3E95-4D5F-825E-F5BD430BDF28Q33385883-F4A72836-8B35-4C40-B2B0-C8A99591C1D8Q33385898-00F39CCE-ACF6-4475-B53E-0704AC5C310FQ33386145-02F8B5B6-97A1-4279-B87A-E46A411790BBQ33386197-D2916D90-0425-45EF-B6FF-EC941B4FAF49Q33386953-52ED7E74-2304-4540-B368-E420600D3483Q33387312-1EADBD3F-4C29-443A-94A9-D385963EEC9DQ33387648-AC0B501D-A4AD-4F14-87EA-0734ACFDBF2CQ33389839-A37E269B-B493-4E87-9F3E-2C43DD5833B2Q33389987-79A47538-1E29-480A-9408-7BC125A42473Q33391327-3D34F9E0-6E3D-4D2F-BF3E-7190AE563A9CQ33392549-A7D5D66B-B72C-4D6A-823E-43C95C7A1261Q33392864-FFDDBFDA-2356-4912-A633-B70DEBAEEAE0Q33393161-D3B3989F-ED30-4111-A537-4F0F0243E95FQ33393585-48E66874-3C64-47E5-8138-C6E05B6EEB13Q33394188-2186E96C-6690-4808-BB2F-C88CB572A37CQ33394695-7D9F0506-0D23-449A-9D1A-CD7EEB4CD0FAQ33394975-3A1F16FD-B8B6-4908-ABF3-5CC63172C24AQ33394986-51958B1E-B7B7-4092-9254-AAF42DEEFE01Q33394988-D2CF9069-D17B-4CB3-8469-0A86837CAB17Q33395238-93D43379-F084-4C55-ABEE-55D3918F24CDQ33395517-B88264CA-7BC6-45CA-91B3-CA2FFC35F9ACQ33397698-23CB12E2-596D-42EA-A8A6-9504941196BAQ33398047-FBD470E4-C8B1-4EC2-B149-E49A7D182425
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Clinical practice. Heparin-induced thrombocytopenia.
@ast
Clinical practice. Heparin-induced thrombocytopenia.
@en
type
label
Clinical practice. Heparin-induced thrombocytopenia.
@ast
Clinical practice. Heparin-induced thrombocytopenia.
@en
prefLabel
Clinical practice. Heparin-induced thrombocytopenia.
@ast
Clinical practice. Heparin-induced thrombocytopenia.
@en
P356
P1476
Clinical practice. Heparin-induced thrombocytopenia.
@en
P2093
Gowthami M Arepally
Thomas L Ortel
P304
P356
10.1056/NEJMCP052967
P407
P577
2006-08-01T00:00:00Z